Annual immunization is the most effective intervention to prevent disease resulting from infection with seasonal influenza virus. The efficacy of currently licensed trivalent seasonal influenza vaccines (TIVs) in preventing laboratory-confirmed influenza infection has been demonstrated in a number of recent placebo-controlled trials \[[@bib1]--[@bib5]\]. However, influenza vaccine efficacy studies have rarely addressed the consistency of vaccine-induced protection; vaccine efficacy is generally reported as a point estimate for the entire study period, irrespective of the chronological distribution of breakthrough infections. Considering that a single vaccination is intended to protect against seasonal influenza epidemics that may occur from early autumn until late spring, further evaluation of the stability of the protection provided by seasonal influenza vaccines is warranted.

Influenza vaccine efficacy can be influenced by a number of factors, including the extent to which individuals are exposed to influenza virus and the degree of antigenic similarity between circulating virus strains and thoseincluded in the vaccine \[[@bib6]\]; in clinical trials, laboratory-confirmed infections are reported in a proportion of subjects despite vaccination. However, little is known about the clinical course of disease in these individuals. Efficacy studies that use laboratory-confirmed influenza infection as a clinical endpoint seldom report the duration or severity of disease associated with breakthrough infections. A reduction in influenzalike illness (ILI) symptoms is frequently used as a less stringent clinical endpoint to demonstrate vaccine effectiveness, but, without laboratory confirmation, it is difficult to infer a causal relationship between vaccination, influenza infection, and disease status \[[@bib7]\].

A recent phase III placebo-controlled trial demonstrated a novel Vero cell culture--derived seasonal influenza vaccine (VCIV) to be 78.5% efficacious against cell culture--confirmed influenza infection (CCII) with antigenically matched virus strains \[[@bib1]\]. In the present study, we undertook additional analyses of data from this trial to assess the consistency of vaccine efficacy over a complete influenza season and to investigate the potential of the vaccine to ameliorate disease symptoms in individuals in which infection is not prevented.

METHODS
=======

Study Design and Objectives
---------------------------

A randomized, double-blind placebo-controlled phase III trial investigating the efficacy of a VCIV has been described elsewhere \[[@bib1]\]. This study was undertaken during the 2008--2009 Northern hemisphere influenza season at 36 centers throughout the United States in healthy young adults aged 18--49 years. The primary study objective was to demonstrate the efficacy of VCIV in preventing CCII due to influenza virus that was antigenically matched to 1 of the vaccine strains. Post hoc analyses were performed to assess the consistency of vaccine efficacy and to determine the effect of vaccination on the duration and severity of disease in infected individuals. The Sterling Institutional Review Board, Atlanta, GA, approved the study protocol and consent forms used in the study, which was conducted in compliance with Good Clinical Practice guidelines and the Declaration of Helsinki. The study employed a 4-member independent Data Monitoring Committee. Individuals who demonstrated an understanding of the study and provided written informed consent were accepted as potential study volunteers.

Vaccination and ILI Follow-up
-----------------------------

Subjects were equally randomized to receive an intramuscular injection of 0.5 mL VCIV or placebo. VCIV is a trivalent split vaccine that was formulated to contain 15 μg of hemagglutinin antigen from each of the vaccine strains A/Brisbane/59/2007 (A/H1N1), A/Uruguay/716/2007 (A/H3N2), and B/Florida/4/2006. Vaccine viruses were egg-derived wild-type strains provided by the National Institute for Biological Standards and Control, Potters Bar, United Kingdom, which were subjected to 3 passages in Vero cell culture prior to vaccine production. Sequence analysis of the production viruses showed that typical mutations resulting from egg growth were retained following culture in Vero cells. Placebo was phosphate-buffered saline.

From 3 weeks postvaccination, subjects were instructed to return to the clinic for an ILI visit within 48 hours of onset of symptoms should they experience fever with cough, sore throat, muscle ache, headache, fatigue, nausea, or bloodshot eyes, or if they should experience any 2 of the listed symptoms in the absence of fever. At every ILI visit, nasopharyngeal swabs were obtained for culturing and typing of viruses.

Assessment of Disease Severity and Duration
-------------------------------------------

ILI duration and severity data were obtained by post hoc review of subjects' case report forms. Disease severity was investigator-assessed and classified as being mild, moderate, or severe. Symptoms that caused transient discomfort, which do not significantly interfere with normal function, and which resolve spontaneously or which may require minimal therapeutic intervention, were classified as mild. Symptoms that caused limited impairment of function, which could require therapeutic intervention but which caused no sequelae, were classified as moderate. Symptoms that resulted in marked impairment of function, which could lead to a temporary inability to resume normal life, and which produced sequelae that required prolonged therapeutic intervention, were classified as severe.

Laboratory Confirmation and Antigenic Typing of Influenza Viruses
-----------------------------------------------------------------

Virus specimens collected using nasopharyngeal swabs at ILI visits were shipped to Bio Analytical Research Corporation, Lake Success, New York, for culture using traditional cell culture and Rapid R-Mix (Diagnostic Hybrids, Athens, Ohio) and virus typing via real-time polymerase chain reaction. The antigenic relatedness of virus isolates to vaccine strains was determined by hemagglutination inhibition analysis at the laboratory of the Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention (CDC). Genetic sequencing was done by GENEWIZ Inc, South Plainfield, New Jersey. Assessment of the genetic lineage of the B strains was performed at the Institute of Virology, Medical University of Vienna, Austria.

Statistical Analyses
--------------------

Calculation of the cumulative weekly vaccine efficacy included all randomly assigned and immunized participants who stayed in the study for at least 21 days after vaccination. Cumulative vaccine efficacy (VE) was computed by the formula VE = (1 − RR) × 100, where RR is the ratio of influenza infection risk in the VCIV group compared with the risk in the placebo group. The 95% confidence interval (CI) of the RR was computed by the method proposed by Miettinen and Nurminen \[[@bib8]\].

Analysis of the duration and severity of ILI symptoms was performed on all subjects with CCII. Subjects were analyzed as randomized; there were no randomization errors in this subset. All the Medical Dictionary for Regulatory Activities (MedDRA) preferred terms of adverse events (ILI symptoms) associated with influenza infection occurring within 3 days from the date of swab collection were listed. If a symptom occurred more than once in any subject, durations were added, whereas severity was considered to be the maximum of the severity scores. Symptoms with an incidence of \<10% were not included in further analyses. To compare the joint distribution of duration and severity between the 2 treatment groups, a bivariate nonparametric permutation-based method (POSET test \[[@bib9]\]) was applied, preceded by a partial ordering procedure on the pairs of data (severity, duration) in order to assign ranks to each pair. No adjustments were made for multiplicity. For each *P* value, 40 000 permutations were generated in order to obtain a standard error of around 0.001.

RESULTS
=======

Study Participants
------------------

The flow of participants through the study is shown in [Figure 1](#fig1){ref-type="fig"}. All study subjects were vaccinated between 1 and 15 December 2008. The baseline characteristics of participants who received either VCIV or placebo is shown in [Table 1](#tbl1){ref-type="table"}. A total of 7243 participants received either VCIV (3623) or placebo (3620). The VCIV and placebo groups were evenly balanced by age and sex. The age range in both groups was 18--49 years, and the median age was 31 and 30 years for the VCIV and placebo groups, respectively. Analysis of swab specimens obtained at ILI visits continued until 15 May; no cell culture--confirmed influenza infections were recorded for specimens collected after the week ending 9 May.

###### 

Baseline Characteristics of Participants Receiving Vero Cell Culture\--Derived Influenza Vaccine or Placebo

  Characteristics                    VCIV (n = 3623)       Placebo (n = 3620)    Overall (n = 7243)
  ---------------------------------- --------------------- --------------------- ---------------------
  Male, No. (%)                      1823 (25.2)           1865 (25.7)           3688 (50.9)
  Female, No. (%)                    1800 (24.9)           1755 (24.2)           3555 (49.1)
  Age, years, mean (SD) \[median\]   32.2 (9.7) \[31.0\]   32.1 (9.7) \[30.0\]   32.1 (9.7) \[31.0\]
  Age range, years                   18--49                18--49                18--49

Abbreviations: SD, standard deviation; VCIV, Vero cell culture--derived influenza vaccine.

![Flow of participants through the study. Abbreviation: VCIV, Vero cell culture--derived influenza vaccine.](cidcir959f01_3c){#fig1}

Consistency of Vaccine Efficacy Throughout an Entire Influenza Season
---------------------------------------------------------------------

To investigate the consistency of vaccine efficacy on a week-by-week basis over the duration of the influenza season, the cumulative frequency of infections occurring in subjects receiving either vaccine or placebo were analyzed. Up to the week ending 17 January 2009, only 7 subjects reporting with ILI were shown to be infected with influenza virus. Six of these subjects had received placebo, with only a single vaccine recipient becoming infected during this period. However, due to the low number of infections, no statistical analysis of the consistency of vaccine efficacy could be carried out until the week ending 24 January 2009.

[Figure 2](#fig2){ref-type="fig"} shows the cumulative efficacy of VCIV in preventing CCII from the week ending 24 January to the week ending 9 May 2009. These data show that vaccine efficacy is consistently high, including for the duration of the entire period from the end of January through mid-March during which influenza activity was above the epidemic threshold \[[@bib10]\]. The weekly cumulative point estimate for vaccine efficacy was 71%--82% against cell culture--confirmed infection with antigenically matched A/H1N1 strains ([Figure 2*A*](#fig2){ref-type="fig"}), 73%--82% for cell culture--confirmed infections with all antigenically matched strains ([Figure 2*B*](#fig2){ref-type="fig"}), and 68%--83% for all cell culture--confirmed infections, irrespective of antigenic similarity to the vaccine strains ([Figure 2*C*](#fig2){ref-type="fig"}). The wider 95% CIs for the point estimates of vaccine efficacy during the first weeks of the observation period are a consequence of the low cumulative number of infections during this period (a total of only 14 infections up to the week ending 31 January), reflecting the fact that the seasonal influenza activity in the United States remained below the national baseline until the end of January and did not peak until mid-February \[[@bib10]\].

![Weekly cumulative vaccine efficacy against cell culture--confirmed influenza infection. Vaccine efficacy could be calculated from 24 January 2009, ∼6 weeks after vaccination of the last subject on 15 December. Analysis of specimens from influenzalike illness visits continued until 15 May; the last laboratory-confirmed influenza infection was recorded in the week ending 9 May 2009.](cidcir959f02_lw){#fig2}

Vaccine efficacy was at least as high in the later stages of the study compared with earlier stages; the weekly cumulative vaccine efficacy from the beginning of March onward was \>78% for antigenically matched A/H1N1 strains, \>77% for all antigenically matched strains, and \>70% for all strains, irrespective of antigenic match. The consistency of vaccine efficacy over time was also investigated by dividing the study into 2 periods and analyzing vaccine efficacy in the first 3 months of the study compared with the period thereafter. In the first period, 10 of 3619 VCIV recipients had antigenically matched CCII compared with 40 of 3617 placebo recipients, such that vaccine efficacy was estimated to be 75.0% (95% CI, 50.8%--87.3%). In the second period, 3 of 3532 VCIV recipients had antigenically matched CCII compared with 20 of 3530 placebo recipients, resulting in vaccine efficacy of 85.0% (95% CI, 52.8%--95.2%). This analysis demonstrates that vaccine efficacy was similar during both periods.

Duration and Severity of ILI Symptoms in VCIV and Placebo Recipients With Cell Culture--Confirmed Influenza Infection
---------------------------------------------------------------------------------------------------------------------

Despite the high efficacy of VCIV in preventing influenza infection, over the duration of the study a total of 21 vaccinated individuals were nevertheless infected with influenza virus as determined by CCII. To investigate the potential of vaccination to ameliorate influenza disease symptoms in subjects in which infection is not prevented, we compared the severity and duration of ILI symptoms in all placebo and VCIV recipients with CCII. For the majority of symptoms, VCIV recipients had a reduced proportion of cases rated moderate or severe and a reduced proportion of cases of longer duration ([Figure 3](#fig3){ref-type="fig"}). VCIV recipients experienced no severe cough, oropharyngeal pain, myalgia, headache, or nausea, and only single cases of severe pyrexia or fatigue. The mean and median duration of all ILI symptoms were reduced for VCIV recipients with the exception of nausea, and the mean severity score of all symptoms was reduced for all VCIV recipients with the exception of pyrexia ([Table 2](#tbl2){ref-type="table"}). Bivariate statistical analyses of the joint benefit of reduction in disease severity and duration show that this is significant for myalgia (*P* = .003), headache (*P* = .025), and fatigue (*P* = .013). There were also reductions in the duration and severity of cough (*P* = .143) and oropharyngeal pain (*P* = .083) for VCIV recipients, although these are not statistically significant.

###### 

Bivariate Analysis of the Severity and Duration of Influenzalike Illness Symptoms Among Subjects With Cell Culture--Confirmed Influenza Infection

                           No. (%) of Subjects With Symptoms                                                        
  ------------------------ ----------------------------------- ----------- ----------- --------- ----- ------------ ------
  VCIV (n = 21)                                                                                                     
      Pyrexia              12 (57)                             5 (23.8)    6 (28.6)    1 (4.8)   1.7   3.6 (3.0)    .491
      Cough                15 (71)                             9 (42.9)    6 (28.6)    0         1.4   8.8 (7.0)    .143
      Oropharyngeal pain   16 (76)                             10 (47.6)   6 (28.6)    0         1.4   7.4 (5.0)    .083
      Myalgia              13 (62)                             8 (38.1)    5 (23.8)    0         1.4   4.2 (3.0)    .003
      Headache             11 (52)                             9 (42.9)    2 (9.5)     0         1.2   5.6 (5.0)    .025
      Fatigue              12 (57)                             8 (38.1)    3 (14.3)    1 (4.8)   1.4   4.9 (3.5)    .013
      Nausea               8 (38)                              5 (23.8)    3 (14.3)    0         1.4   6.9 (6.0)    .479
  Placebo (n = 74)                                                                                                  
      Pyrexia              48 (65)                             26 (35.1)   17 (23.0)   5 (6.8)   1.6   4.4 (3.5)    ...
      Cough                63 (85)                             28 (37.8)   30 (40.5)   5 (6.8)   1.6   10.0 (8.0)   ...
      Oropharyngeal pain   43 (58)                             21 (28.4)   19 (25.7)   3 (4.1)   1.6   8.1 (7.0)    ...
      Myalgia              51 (69)                             20 (27.0)   29 (39.2)   2 (2.7)   1.6   7.8 (7.0)    ...
      Headache             45 (61)                             24 (32.4)   17 (23.0)   4 (5.4)   1.6   7.1 (6.0)    ...
      Fatigue              42 (57)                             19 (25.7)   21 (28.4)   2 (2.7)   1.6   7.4 (6.0)    ...
      Nausea               21 (28)                             11 (14.9)   10 (13.5)   0         1.5   5.1 (5.0)    ...

Abbreviations: ILI, influenzalike illness; VCIV, Vero cell culture--derived influenza vaccine.

Symptoms rated as mild were given a score of 1, moderate symptoms a score of 2, and severe symptoms a score of 3.

*P* value (POSET test) of the reduction in severity and duration of symptoms in VCIV recipients compared with placebo recipients.

![Amelioration of disease symptoms in subjects with cell culture--confirmed influenza infection. Symptoms are rated as severe (red), moderate (orange), or mild (green). ^a^Four placebo recipients had cough for \>20 days. Three were rated as moderate (31, 35, and 51 days duration), and 1 was rated as severe (22 days duration). ^b^One recipient of Vero cell culture--derived influenza vaccine had oropharyngeal pain for 31 days, rated moderate. Abbreviation: VCIV, Vero cell culture\--derived influenza vaccine.](cidcir959f03_3c){#fig3}

DISCUSSION
==========

We investigated the consistency of protection induced by a novel Vero cell culture--derived seasonal influenza vaccine in the United States in 2008--2009. Only low levels of influenza activity were detected up until mid-January 2009, but activity increased in mid-January, peaking in mid-February, and remaining high until mid-March \[[@bib10]\]. The Vero-derived vaccine was consistently highly efficacious in preventing laboratory-confirmed influenza infection over this entire period ([Figure 2](#fig2){ref-type="fig"}). Importantly, vaccine efficacy did not wane as the influenza season progressed; the weekly cumulative vaccine efficacy from the beginning of March onward was \>78% for antigenically matched A/H1N1 strains, \>77% for all antigenically matched strains, and \>70% for all strains, irrespective of antigenic match. This is also demonstrated by the similarly high estimates of vaccine efficacy for antigenically matched strains in the first 3 months of the study (75.0%) compared with the period thereafter (85.0%). Because subjects were vaccinated in December, our study does not allow us to be certain that vaccine efficacy would be maintained at equally high levels to the end of an influenza season if vaccination were to be initiated at an earlier time point, as recommended by the CDC \[[@bib11]\]. However, as there was no indication of a reduction in vaccine efficacy up to 5 months after vaccination, it seems likely that earlier vaccination would also provide season-long protection.

Other studies assessing the longevity or consistency of vaccine efficacy against infection with seasonal influenza virus are limited. Historically, monovalent vaccines were reported to provide extended protection against the Hong Kong \[[@bib12], [@bib13]\] and Russian pandemic strain viruses \[[@bib14]\]. More recent studies have reported a trivalent live-attenuated influenza vaccine (LAIV) to provide stable levels of protection against CCII for up to 12 months in children \[[@bib15]\], and, in comparative studies, LAIV was relatively more efficacious than TIV in preventing CCII \>4--8 months postvaccination compared to 0\--4 months postvaccination \[[@bib16]\]. To our knowledge, the consistency of the protective efficacy of modern split or subunit TIVs compared with placebo has not previously been demonstrated in any population.

The cumulative vaccine efficacy estimates and efficacy up to or after 3 months reported here for the Vero-derived vaccine are similar to those determined for the entire study period, where vaccine efficacy was estimated to be 79% for antigenically matched A/H1N1 strains, 78.5% for all matched strains, and 71.5% for all strains, irrespective of antigenic match \[[@bib1]\]. It is difficult to compare absolute vaccine efficacy between independent studies due to a number of factors that cause heterogeneity between different studies, such as differences in virus strains, attack rate of circulating viruses, and clinical endpoints used; however, these efficacy estimates are in the upper range of those reported in other recent studies of seasonal influenza vaccines \[[@bib2]--[@bib5], [@bib17], [@bib18]\] and similar to or higher than those reported in recent meta-analyses of TIV efficacy \[[@bib19], [@bib20]\].

A proportion of individuals were infected with influenza virus despite vaccination. However, our results demonstrate that the benefit of vaccination extends beyond the prevention of infection, because the majority of ILI symptoms in subjects with CCII were both milder and of shorter duration in vaccine recipients compared with placebo recipients ([Figure 3](#fig3){ref-type="fig"}). In the cases of myalgia (*P* = .003), headache (*P* = .025), and fatigue (*P* = .013), the joint reduction in disease duration and severity was statistically significant ([Table 2](#tbl2){ref-type="table"}). The demonstration of statistical significance of VCIV in amelioration of disease is noteworthy in the context of the high efficacy of the vaccine in preventing influenza infection. This resulted in a small sample size for infected VCIV recipients and, consequently, a lower power of analysis, such that a larger effect is necessary to demonstrate statistical significance of disease amelioration than would be the case for a less efficacious vaccine. Amelioration of cough (*P* = .143) and oropharyngeal pain (*P* = .083) was also observed. The reduction in the severity and duration of these symptoms may also be clinically relevant, although the small sample size precluded the calculation of a statistically significant benefit.

Previous investigations into the potential of influenza vaccines to ameliorate disease in subjects with laboratory-confirmed influenza infection have been limited to a restricted selection of ILI symptoms, and few statistically significant reductions in the severity or duration of disease symptoms have been reported. A small number of studies have reported significant reductions in fever for TIV \[[@bib21]\] or LAIV \[[@bib22]\] recipients, or have shown a significant benefit of LAIV over TIV for the reduction of fever in children \[[@bib23]\] or older adults \[[@bib24]\]. Both TIV and LAIV have also been reported to reduce the rate of acute otitis media (AOM) in children \[[@bib25]\]; we did not investigate the occurrence of AOM because our study was of young healthy adults, and AOM is not a common symptom of influenza infection in this population. Prevention of infection and disease in vaccinated individuals also has the potential to benefit nonvaccinated contacts by preventing or reducing virus transmission. In this respect, the level of virus shedding in individuals who were infected despite vaccination would also be of interest. Our study did not include a quantitative assay for detection of virus in nasopharyngeal specimens; however, other studies have suggested that virus shedding may be less effectively reduced in recipients of TIV compared with recipients of LAIV \[[@bib26]--[@bib28]\].

The conclusions of our study are subject to the limitations that are inherent to any post hoc analyses of study data. In addition, because no study arm with an egg-derived vaccine was included, we cannot make a direct comparison of vaccines produced in Vero cell culture or using standard technology. Other limitations are that due to the nature of the 2008--2009 influenza season, data are primarily for the A/H1N1 strain and only for adults aged 18--49 years because vaccination was recommended for all other populations in the United States at the time of the study. However, the potential clinical and socioeconomic benefits of vaccination in younger adults are also substantial \[[@bib29]--[@bib31]\], as reflected in the global drive to increase vaccine coverage beyond traditional high-risk groups. In the United States, annual vaccination is now recommended for all individuals above the age of 6 months \[[@bib32]\], and it is the aim of the US Healthy People 2020 goals to achieve 80%--90% vaccine coverage \[[@bib33]\]. Improvements in influenza vaccine supply may be required to achieve these goals, and the availability of modern, robust, and flexible manufacturing technologies will facilitate this process \[[@bib34], [@bib35]\]. The present study makes an important contribution to a growing body of evidence supporting the use of cell culture technology for vaccine manufacture.
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